- Home
- NVCT
NVCT
Nuvectis Pharma Inc.
as 05-09-2025 4:00pm EST
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | FORT LEE |
| Market Cap: | 249.1M | IPO Year: | 2022 |
| Target Price: | $17.00 | AVG Volume (30 days): | 157.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.44 - $11.80 | Next Earning Date: | 05-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Nuvectis Pharma Inc. News
NVCT Breaking Stock News: Dive into NVCT Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans
GlobeNewswire
3 days ago
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
Insider Monkey
10 days ago
Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025
GlobeNewswire
10 days ago
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
MT Newswires
a month ago
Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target
GlobeNewswire
a month ago
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
GlobeNewswire
2 months ago
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
Business Wire
2 months ago
Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
Compare NVCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCT Nuvectis Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.